Navigation Links
ProNAi Announces Preclinical Success for PNT2258 Therapeutic -,Curative Events in Xenograft Mice for Difficult-to-Treat,Non-Hodgkin's Lymphoma

LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 - ProNAi Therapeutics, Inc., a biopharmaceutical company pioneering a new class of nucleic-acid drugs based on DNA interference (DNAi), today announced that its lead oncology therapeutic candidate, PNT2258, has successfully demonstrated preclinical in vivo efficacy in xenograft mice for a number of human cancers - including curative events for difficult-to-treat Burkitt's Lymphoma.

Dr. Richard D. Gill, President and CEO of ProNAi, said, "Team ProNAi is quite pleased with our early preclinical results for PNT2258. Particularly encouraging is the fact that PNT2258 has shown promising single agent efficacy and combination therapy efficacy and drug-dose response for multiple cancer types including both hematological and solid tumors."

He added, "However, a very exciting development was our discovery that PNT2258, in combination with Rituximab, demonstrated curative events in treating Daudi xenografts of human Burkitt's Lymphoma in mice. The antitumor effect was rapid and durable. We had 70% complete remissions in two groups of animals dosed with PNT2258 and Rituximab."

In developing its DNAi(R)-based therapy, ProNAi reports that its successful establishment of in vivo efficacy for formulated PNT2258 included:

-- Single agent efficacy for DLCL2 Xenografts of Human Non-Hodgkin's Lymphoma

-- Combination therapy efficacy with Docetaxel for Human Hormone Refractory Prostate Cancer Xenograft

-- Combination therapy with Rituximab in Daudi Xenografts of Human Burkitt's Lymphoma

ProNAi's preclinical research will proceed in 2007. Planned studies include IND-enabling toxicology and ADME studies. ProNAi will file the IND for PNT2258 later this year.

About DNAi(R)

DNAi(R) (DNA interference) is a novel approach to targeting genomic DNA using sequence-specific therapeutic oligonucleotides, employing single strands of DNA to target
'"/>




Page: 1 2

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:1/14/2014)... Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s ... a targeting guide with accompanying instrumentation to place and ... adjunct to the soft tissue (e.g. ligament) repair or ... tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... 2014 NineSigma , Inc., the leading innovation ... Leadership Summit , May 14-16, 2014 at the Global ... . This is the premier ... breakthrough achievements through open innovation. Participants will learn how ...
(Date:1/14/2014)... 14, 2014   Evidera , a leading provider of ... Center for Drug Evaluation and Research (CDER), U.S. Food ... guidance document for a patient-reported outcome (PRO) measure in ... Disease Tool [EXACT] for Measurement of Symptoms of Acute ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 2Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 3Expect the Unexpected from Leading Global Innovators at NineSigma Leadership Summit, Sharing Winning Strategies to Advance Innovation 4Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 2Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 3Evidera Announces Release of FDA Draft Guidance on Use of the "EXACT" to Measure Symptoms of COPD Exacerbations 4
... Medarex, Inc. (Nasdaq:, MEDX ) announced today ... non-fucosylated version of MDX-060 that targets CD30, a,marker ... malignant cells of,Hodgkin,s lymphoma (HL) as well as ... potency and efficacy in cell lines when,compared to ...
... TEL AVIV, Israel, December 8 InspireMD, Ltd. announced,that ... use in Israel,by the Israeli Ministry of Health. , ... system presents a novel combination of a coronary,stent merged ... by an expandable, flexible fishnet style, micron level knit,sleeve ...
Cached Medicine Technology:Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma 2Medarex Announces Enhanced Activity Data with Second Generation Anti-CD30 Antibody for Malignant Lymphoma 3MGuard(TM) Coronary Stent System Approved in Israel 2MGuard(TM) Coronary Stent System Approved in Israel 3
(Date:4/17/2014)... most popular vaccine brands for children may not be ... some cost factors when choosing vaccines, driving the market ... to a new study by University of Illinois researchers. ... driven by numerous factors," says Sheldon H. Jacobson, a ... science and of mathematics at the U. of I. ...
(Date:4/17/2014)... the University of California, San Diego School of Medicine ... have suffered a recent major loss are more likely ... , The study is published in this month,s issue ... , Because compassionate behaviors are associated with better health ... insights into ways to improve the outcomes of individuals ...
(Date:4/17/2014)... MD, was recently invited to submit a review ... Microbiology , one of the world,s foremost scientific ... specialist, and chair of the Department of Pediatrics ... analyzed the epidemiology and microbiology of co-infections during ... as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... about one in five infants in the United States ... first several months after birth. Research into probiotic use ... the April 1, 2014 issue of the British ... study, "Probiotics and Infant Colic," concluding that the use ... colic did not reduce crying or fussing in ...
Breaking Medicine News(10 mins):Health News:Study recalculates costs of combination vaccines 2Health News:The ilk of human kindness 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... the reason why isolated women are less vulnerable to falling ill ... ,The study is an eye-opener to the upcoming proof that ... a clue to the reason why socially isolated men are prone ... have shown a connection between stress and immune function. But this ...
... Bachoud-Lévi, M.D., and colleagues of the French national institute ... Huntington's disease// who previously received intracerebral fetal neural grafts ... ,But the same investigators reported today that ... years and then began to decline over the next ...
... at University of California have gained valuable insights about ... , a finding that may eventually accelerate current research ... is a joint effort by Dr. Frank Sauer (UCR ... Munich) and other researchers from University of California. The ...
... School of Public Health are one of the 14 ... Environmental Health Sciences// (NIEHS) to study the association between ... is a new study to control the rising obesity ... an individual’s body size. Working with various city departments, ...
... Research Institutes, Inc (NDRI) in New York City ... the role// of social supports, spirituality, religiousness, life ... recovery from addiction. The study reveals markedly improved ... a decrease in stress when people were inclined ...
... fear regarding the elevated risk of lymphoma associated with ... has found that such treatments may not confer an ... be seen in the latest issue of Arthritis & ... been found to increase with worsening of the chronic ...
Cached Medicine News:Health News:Women Portray Stronger Immune Response As Compared to Men, Study Suggests 2Health News:Fetal Neural Grafts Improves Motor and Cognitive Function in Huntington Patients 2Health News:Drug Addiction Recovery Buffered by Spirituality 2Health News:No Lymphoma Risk From Rheumatoid Arthritis Drugs 2
Flattened points in vertical plane, straight shafts, cross action, round handle....
... cross action. Round handle. Divides nucleus for ... Nuclei of any hardness can be pre-chopped ... of pre-chopped nuclear fragments is rapid. Risk ... diminished. Shortened ultra sound time and minimal ...
1.5 mm inner cutting edge....
Nucleus chopper....
Medicine Products: